91 related articles for article (PubMed ID: 8758481)
21. Precipitation of amphotericin B from i.v. fat emulsion.
Heide PE
Am J Health Syst Pharm; 1997 Jun; 54(12):1449. PubMed ID: 9194992
[No Abstract] [Full Text] [Related]
22. Fatal fat embolism following amphotericin B lipid complex injection.
Tolentino LF; Tsai SF; Witt MD; French SW
Exp Mol Pathol; 2004 Dec; 77(3):246-8. PubMed ID: 15507243
[TBL] [Abstract][Full Text] [Related]
23. Stability of amphotericin B and nystatin in antifungal mouthrinses containing sodium hydrogen carbonate.
Groeschke J; Solassol I; Bressolle F; Pinguet F
J Pharm Biomed Anal; 2006 Sep; 42(3):362-6. PubMed ID: 16740372
[TBL] [Abstract][Full Text] [Related]
24. Lipid formulations of amphotericin B.
Dix SP; Andriole VT
Curr Clin Top Infect Dis; 2000; 20():1-23. PubMed ID: 10943516
[TBL] [Abstract][Full Text] [Related]
25. Safety of a pre-formulated amphotericin B lipid emulsion for the treatment of Indian Kala-azar.
Sundar S; Chakravarty J; Agarwal D; Shah A; Agrawal N; Rai M
Trop Med Int Health; 2008 Sep; 13(9):1208-12. PubMed ID: 18664241
[TBL] [Abstract][Full Text] [Related]
26. Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study.
Schöffski P; Freund M; Wunder R; Petersen D; Köhne CH; Hecker H; Schubert U; Ganser A
BMJ; 1998 Aug; 317(7155):379-84. PubMed ID: 9694753
[TBL] [Abstract][Full Text] [Related]
27. Differences in pharmacokinetics of amphotericin B lipid formulations despite clinical equivalence.
Bellmann R; Egger P; Wiedermann CJ
Clin Infect Dis; 2003 Jun; 36(11):1500-1. PubMed ID: 12766850
[No Abstract] [Full Text] [Related]
28. Peritoneal penetration of amphotericin B lipid complex and fluconazole in a pediatric patient with fungal peritonitis.
Blowey DL; Garg UC; Kearns GL; Warady BA
Adv Perit Dial; 1998; 14():247-50. PubMed ID: 10649734
[TBL] [Abstract][Full Text] [Related]
29. Implementation of clinical practice policy on the continuous intravenous administration of amphotericin B deoxycholate.
Maharom P; Thamlikitkul V
J Med Assoc Thai; 2006 Nov; 89 Suppl 5():S118-24. PubMed ID: 17718252
[TBL] [Abstract][Full Text] [Related]
30. Acute renal failure with amphotericin B in lipid emulsion.
Gales MA; Gales BJ; Alford KM
Ann Pharmacother; 1996 Sep; 30(9):1036. PubMed ID: 8876871
[No Abstract] [Full Text] [Related]
31. Long-term stability of lipid emulsions with parenteral nutrition solutions.
Tannuri U; Sesso A; Coelho MC; Maksoud JG
Nutrition; 1992; 8(2):98-100. PubMed ID: 1591460
[TBL] [Abstract][Full Text] [Related]
32. [Stability testing of amphotericin B nasal spray solutions with chemical and biological analysis].
Fittler A; Mayer A; Kocsis B; Gerlinger I; Fónay F; Botz L
Acta Pharm Hung; 2007; 77(3):159-64. PubMed ID: 18019780
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of conventional formulation versus fat emulsion formulation of amphotericin B in a group of patients with neutropenia.
Ayestarán A; López RM; Montoro JB; Estíbalez A; Pou L; Julià A; López A; Pascual B
Antimicrob Agents Chemother; 1996 Mar; 40(3):609-12. PubMed ID: 8851579
[TBL] [Abstract][Full Text] [Related]
34. The influence of electrolytes on fat emulsions stability in total parenteral nutrition mixtures.
Grzegorzewska I; Czarnecki A
Acta Pol Pharm; 1995; 52(1):17-20. PubMed ID: 8960235
[TBL] [Abstract][Full Text] [Related]
35. The reformulation of amphotericin B for oral administration to treat systemic fungal infections and visceral leishmaniasis.
Thornton SJ; Wasan KM
Expert Opin Drug Deliv; 2009 Mar; 6(3):271-84. PubMed ID: 19327044
[TBL] [Abstract][Full Text] [Related]
36. Amphotericin B-entrapping lipid nanoparticles and their in vitro and in vivo characteristics.
Jung SH; Lim DH; Jung SH; Lee JE; Jeong KS; Seong H; Shin BC
Eur J Pharm Sci; 2009 Jun; 37(3-4):313-20. PubMed ID: 19491021
[TBL] [Abstract][Full Text] [Related]
37. In vivo distribution and therapeutic efficacy of a novel amphotericin B poly-aggregated formulation.
Espada R; Valdespina S; Dea MA; Molero G; Ballesteros MP; Bolás F; Torrado JJ
J Antimicrob Chemother; 2008 May; 61(5):1125-31. PubMed ID: 18285313
[TBL] [Abstract][Full Text] [Related]
38. Hyperkalemia associated with rapid infusion of conventional and lipid complex formulations of amphotericin B.
Barcia JP
Pharmacotherapy; 1998; 18(4):874-6. PubMed ID: 9692667
[TBL] [Abstract][Full Text] [Related]
39. Amphotericin B in fat emulsion.
Kintzel PE
Am J Health Syst Pharm; 1996 Nov; 53(22):2701. PubMed ID: 8931810
[No Abstract] [Full Text] [Related]
40. Amphotericin B deoxycholate: no significant advantage of a 24 h over a 6 h infusion schedule.
Altmannsberger P; Holler E; Andreesen R; Krause SW
J Antimicrob Chemother; 2007 Jul; 60(1):180-2. PubMed ID: 17537868
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
